ProCE Banner Activity

CME

Key COVID-19 Studies Influencing My Practice Following ECCMID 2022

Conference Coverage
Multimedia

Hear from CCO’s expert faculty as they present insights on some of the most clinically relevant new COVID-19 data presented at ECCMID 2022, including data on antiviral agents, monoclonal antibodies, IL-6 inhibitors, COVID-19 vaccination, and long COVID.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: May 18, 2022

Expiration: May 17, 2023

No longer available for credit.

Share

Faculty

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients at risk of or diagnosed with COVID-19.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Interpret findings of studies on long COVID
  • Apply safety and efficacy data from recent clinical studies of evolving therapeutics for SARS-CoV-2 in ongoing treatment of patients with COVID-19
  • Integrate new data from studies of vaccines and monoclonal antibodies into prevention and treatment strategies for SARS-CoV-2 infection

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD, has disclosed that she has received consulting fees from AbbVie, Angelini, Gilead Sciences, Janssen, MSD, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, has disclosed that she has individual publicly traded stocks and stock options with Abbott Laboratories, Becton Dickinson, Johnson & Johnson, and Merck.

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category l Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 18, 2022, through May 17, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve learners’ competence in translating the most clinically significant data from ECCMID 2022 into practical management strategies for individuals at risk of or diagnosed with COVID-19.